Merck & Co., Inc. (NYSE:MRK) is considered one of the most profitable healthcare stocks to buy. BofA analysts included MRK in its “US 1 List,” with an unchanged price target of $95. Bernstein raised concerns about growth prospects beyond Keytruda and highlighted MRK’s focus on M&As, with a consensus 1-year median price target of $120.

With mixed analyst sentiment, slightly more than half recommend buying MRK. The company, founded in 1891 in New Jersey, develops and manufactures human health pharmaceuticals. Analysts see a 10.93% upside potential for MRK, but suggest exploring other AI stocks for greater returns and lower risks.

Read more at Yahoo Finance: Merck & Co., Inc. (MRK) Joins BofA’s “US 1 List”